6 recruiting, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 10 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 6, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 8 | Recruiting 5, Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow Mezigdomide: new trials by email Literature Review of Mezigdomide trials Research Report on Mezigdomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Dexamethasone, Mezigdomide, Elranatamab - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Not yet recruiting | PETHEMA Foundation | 60 | 2026-11-01 | 2026-10-28 |
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Celgene | 62 | 2025-10-07 | 2026-09-02 |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations Etentamig, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AbbVie | 602 | 2025-06-30 | 2026-10-19 |
| Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease Mezigdomide, Carfilzomib, Dexamethasone - Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 28 | 2025-05-01 | 2026-08-18 |
| Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Recruiting | YOUNGIL KOH | 75 | 2024-11-26 | 2025-12-03 |
| Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma Mezigdomide, Ixazomib, Dexamethasone - Relapsed and Refractory Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | Kathleen Dorritie | 2023-10-02 | 2024-11-19 | |
| A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) CC-92480, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Celgene | 424 | 2019-09-30 | 2024-11-29 |
| A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) CC-92480, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Celgene | 200 | 2018-02-06 | 2026-02-09 |
| Selinexor and Backbone Treatments of Multiple Myeloma Patients Selinexor, Dexamethasone, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Karyopharm Therapeutics Inc | 300 | 2015-10-01 | 2026-07-15 |
Multiple Myeloma (9) · Recurrence (4) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid, Acute (1) · Neoplasm, Residual (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Celgene (3) · AbbVie (1) · Karyopharm Therapeutics Inc (1) · Kathleen Dorritie (1) · Memorial Sloan Kettering Cancer Center (1) · PETHEMA Foundation (1) · Roswell Park Cancer Institute (1) · YOUNGIL KOH (1)
United States (7) · Canada (4) · Spain (4) · Greece (3) · United Kingdom (3) · Australia (2) · Denmark (2) · Germany (2) · Japan (2) · Norway (2) · South Korea (2) · Belgium (1) · China (1) · Czechia (1) · Finland (1)
Albert Oriol, PhD (1) · Enrique Ocio, PhD (1) · Jens Hillengass, MD (1) · Kathleen A Dorritie, MD (1) · Kuo-Kai Chin, MD (1)
PMID 30352784, PMID 37393120, PMID 37646702, PMID 38826786
2017 (1), 2023 (1), 2025 (1)